Trial Profile
A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-negative Inflammatory Breast Cancer (IBC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Carcinoma; Inflammatory breast cancer; Male breast cancer
- Focus Therapeutic Use
- 29 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2018 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.